Effects of Ultrasound-Guided Thoracic Paravertebral Nerve Block Combined with Perineural or IV Dexmedetomidine on Acute and Chronic Pain After Thoracoscopic Resection of Lung Lesions: A Double-Blind Randomized Trial.

Background: Thoracic paravertebral block (TPVB) analgesia can be prolonged by local anesthetic adjuvants such as dexmedetomidine. This study aimed to evaluate the two administration routes of dexmedetomidine on acute pain and chronic neuropathic pain (NeuP) prevention compared with no dexmedetomidine. Methods: A total of 216 patients were randomized to receive TPVB using 0.4% ropivacaine alone (R Group), with perineural dexmedetomidine 0.5 µg·kg-1 (RD0.5 Group) or 1.0 µg·kg-1 (RD1.0 Group), or intravenous (IV) dexmedetomidine 0.5 µg·kg-1·h-1 (RDiv Group). The primary outcome was the incidence of chronic NeuP, defined as a Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain score > 12 points at 3-month after surgery. Results: (1) For the primary outcome, RD0.5 Group and RD1.0 Group demonstrated a decreased incidence of chronic NeuP at 3-month after surgery; (2) Compared with R Group, RDiv Group, RD0.5 Group, and RD1.0 Group can reduce VAS scores at rest and movement and Prince-Henry Pain scores at 12 and 24-h after surgery, the consumption of oral morphine equivalent (OME) and improve QOD-15 at POD1; (3) Compared with RDiv Group, RD0.5 Group and RD1.0 Group can reduce VAS scores at rest and movement and Prince-Henry Pain scores at 12 and 24-h after surgery, the consumption of postoperative OME and improve QOD-15 at POD1; (4) Compared with RD0.5 Group, RD1.0 Group effectively reduced VAS scores at rest at 12 and 24-h after surgery, VAS scores in movement and Prince-Henry Pain scores at 12-h after surgery. However, RD1.0 Group showed an increased incidence of drowsiness. Conclusion: Perineural or IV dexmedetomidine are similarly effective in reducing acute pain, but only perineural dexmedetomidine reduced chronic NeuP. Moreover, considering postoperative complications such as drowsiness, perineural dexmedetomidine (0.5 µg·kg-1) may be a more appropriate choice. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2200058982).

[Effect of L-arabinose on the postprandial blood glucose and body weight].

OBJECTIVE: To study the effect of L-arabinose on the blood glucose level of adult, and to find out the optimal amount of daily L-arabinose intake for maintaining their health. METHODS: 50 adult were randomly selected and assigned to 5 group with different dose of L-arabinose or placebo, respectively. The preprandial blood glucose level and 1 h and 2h postprandial blood glucose were detected per 3 days. To investigate the variation of weight, 20 fat person was performed with daily L-arabinose or placebo intake for given daily for six months. Results After 30 days feeding, the decrease of postprandial blood glucose level was observed in group with 3% L-arabinose sample, and the groups with 5% - 10% have a significantly decreasing in the postprandial blood glucose level compared with control group result in (5.60 +/- 0.08) and (5.24 +/- 0.12), respectively (P < 0.05). The average body weight have a significantly reduce and after six months averagely reduced 5.5 kg, and the control group have no obviously variation. CONCLUSION: The daily consumption of L-arabinose would inhibit the postprandial blood glucose level and slimming down body which have a benefit for heath.